Nouveautés dans la pathophysiologie et le traitement de l’anémie rénale [New insights in the pathophysiology and treatment of renal anemia]

Details

Ressource 1Request a copy Under embargo until 01/10/2023.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_C48E5B4F4AB8
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Nouveautés dans la pathophysiologie et le traitement de l’anémie rénale [New insights in the pathophysiology and treatment of renal anemia]
Journal
Revue medicale suisse
Author(s)
Vultaggio P., Loria F., Fakhouri F., Leuenberger N., Pruijm M.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
02/03/2022
Peer-reviewed
Oui
Volume
18
Number
771
Pages
358-363
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Renal anemia is a frequently encountered complication in patients suffering from advanced chronic kidney disease. This is mainly due to the decreased secretion of erythropoietin by the diseased kidneys. The current treatment of renal anemia is based on iron substitution and administration of recombinant erythropoietin. The discovery of HIF (Hypoxia-Inducible Factor) has led to the development of a new class of molecules that block the activity of prolyl-4-hydroxylases and stabilize HIF (Hypoxia-Inducible Factor), a transcription factor that plays an essential role in numerous cellular pathways, including those linked to erythropoiesis and iron metabolism. In this article, we discuss the current understanding of the pathophysiological mechanisms underlying renal anemia and the potential role of the new HIF-stabilizers in its treatment.
Keywords
Anemia/etiology, Anemia/therapy, Erythropoiesis, Erythropoietin/metabolism, Erythropoietin/therapeutic use, Humans, Hypoxia-Inducible Factor-Proline Dioxygenases/metabolism, Iron/therapeutic use, Renal Insufficiency, Chronic/complications, Renal Insufficiency, Chronic/therapy
Pubmed
Create date
14/03/2022 10:16
Last modification date
15/06/2022 7:12
Usage data